Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

survivin-targeted vaccine OVM-200

A cancer vaccine consisting of recombinant overlapping peptides (ROPs) derived from the anti-apoptosis protein survivin, with potential immunopotentiating and antineoplastic activities. Upon administration, survivin-targeted vaccine OVM-200 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against survivin-expressing tumor cells, resulting in decreased tumor cell proliferation and tumor cell death. The survivin protein inhibits caspase activation and apoptosis; it is undetectable in normal adult tissues but is expressed by several human cancers including lung, colon, breast, pancreas, and prostate cancer as well as hematopoietic malignancies and skin cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:survivin peptides vaccine OVM-200
survivin recombinant overlapping peptides vaccine OVM-200
survivin ROPs vaccine OVM-200
survivin-targeting cancer vaccine OVM-200
Code name:OVM 200
OVM-200
OVM200
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search